Products for Research Use Only

Pirfenidone-d5

CAT: 0804-HY-B0673S-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0673S-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Pirfenidone-d5 (AMR69-d5) is a deuterium labeled Pirfenidone. Pirfenidone is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities[1][2][3].
CAS Number
1020719-62-3
Product Name Alternative
AMR69-d5
UNSPSC
12352005
Hazard Statement
H302
Target
CCR; TGF-beta/Smad
Type
Isotope-Labeled Compounds
Related Pathways
GPCR/G Protein; Immunology/Inflammation; Stem Cell/Wnt; TGF-beta/Smad
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Purity
98.88
Solubility
DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C1C=CC(C)=CN1C2=C([2H])C([2H])=C([2H])C([2H])=C2[2H]
Molecular Formula
C12H6D5NO
Molecular Weight
190.25
Precautions
P264-P270-P330-P501
References & Citations
[1]Burghardt I, et al. Pirfenidone inhibits TGF-beta expression in malignant glioma cells. Biochem Biophys Res Commun. 2007 Mar 9;354 (2) :542-7.|[2]Nakazato H, et al. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol. 2002 Jun 20;446 (1-3) :177-85.|[3]Inomata M, et al. Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis. Respir Res. 2014 Feb 8;15:16.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported